期刊
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
卷 14, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/17562848211018654
关键词
C; difficile; cost-effectiveness; economic burden
资金
- Crohn's and Colitis Foundation
- Chleck Family Foundation
Clostridioides difficile is the most common cause of healthcare-associated diarrhea, with recurrent infections and disease complications leading to high morbidity and mortality. CDI has a significant economic impact on both the healthcare system and patients, and newer treatment options like fidaxomicin and fecal microbiota transplantation have shown to be more cost-effective in preventing recurrences.
Clostridioides difficile is the most common cause of healthcare-associated diarrhea. Disease complications as well as recurrent infections contribute significantly to morbidity and mortality. Over the past decades, there has been a rapid increase in the incidence of C. difficile infection (CDI), with a rise in the number of community-acquired cases. CDI has a profound economic impact on both the healthcare system and patients, secondary to recurrences, hospitalization, prolonged length of stay, cost of treatment, and indirect societal costs. With emergence of newer treatment options, the standard of care is shifting from metronidazole and vancomycin towards fidaxomicin and fecal microbiota transplantation (FMT), which despite being more expensive, are more efficacious in preventing recurrences and hence overall are more beneficial forms of therapy per cost-effectiveness analyses. Data regarding preferred route of FMT, timing of FMT, and non-conventional therapies such as bezlotoxumab is scant. There is a need for further studies to elucidate the true attributable costs of CDI as well as continued cost-effectiveness research to reduce the economic burden associated with the disease and improve clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据